ArriVent BioPharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2021-01-01
- Employees
- 40
- Market Cap
- $931M
- Website
- http://www.arrivent.com
Clinical Trials
7
Active:5
Completed:0
Trial Phases
2 Phases
Phase 1:3
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (60.0%)Phase 3
2 (40.0%)Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Phase 3
Active, not recruiting
- Conditions
- Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung CancerEGFR Exon 20 Mutations
- Interventions
- Drug: platinum-based chemotherapy
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- ArriVent BioPharma, Inc.
- Target Recruit Count
- 398
- Registration Number
- NCT05607550
- Locations
- 🇬🇧
Arrivent Investigative Site, Bebington, Wirral, United Kingdom
🇺🇸Arrivent Investigative site, Sacramento, California, United States
🇬🇧ArriVent Investigative Site, Sutton, United Kingdom
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
Phase 1
Active, not recruiting
- Conditions
- EGFR Exon 20 MutationsHER2 Exon 20 MutationsMetastatic Non-Small Cell Lung CancerNon-Small Cell Lung Cancer (NSCLC)Advanced Non-Small Cell Lung CancerEGFR Uncommon Mutations, Including G719X and S768I
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2025-08-21
- Lead Sponsor
- ArriVent BioPharma, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT05364073
- Locations
- 🇬🇧
ArriVent Investigative Site, London, United Kingdom
🇳🇱Arrivent Investigative Site, Amsterdam, Noord-Holland, Netherlands
🇨🇳Allist Investigative Site, Taiyuan, Shanxi, China
News
No news found